• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

First-time generic approvals

Article

A discussion of generic drugs recently approved by FDA

Key Points

Ranitidine oral solution, 15 mg/mL (equiv to Zantac syrup)
ACTAVIS

Didanosine for oral solution, 10 mg/mL (equiv to Videx Pediatric Powder for oral solution)
AUROBINDO

Moexipril/hydrochlorothiazide tablets, 12.5/7.5 mg, 25/15 mg, and 12.5/15 mg (equiv to Uniretic tablets)
TEVA

Related Content
© 2024 MJH Life Sciences

All rights reserved.